Evidence map›Paper›PMID 41704534›Full record

Observational studyFrontiers in immunology2025

Sex-specific differences in abscopal responses to combined radiotherapy and immune checkpoint inhibition-insights from a multicenter study.

Maike Trommer, Alexander Rühle, Felix Ehret, Allison Lamrani, Charlotte Schmitter, Justus Kaufmann, Matthias Mäurer, Georg Wurschi, Ping Jiang, Andrea Baehr and 15 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Gender disparities in historical context, workforce structure, and decision-making.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Maike TrommerDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Bonn, Bonn, Germany.
Alexander RühleDepartment of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Felix EhretDepartment of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Allison LamraniDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Charlotte SchmitterDepartment of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Justus KaufmannDepartment of Radiation Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Matthias MäurerDepartment of Radiotherapy and Radiation Oncology, Jena University Hospital, Jena, Germany.
Georg WurschiDepartment of Radiotherapy and Radiation Oncology, Jena University Hospital, Jena, Germany.
Ping JiangClinic for Radiation Oncology and Radiotherapy, Lüdenscheid Clinic, Lüdenscheid, Germany.
Andrea BaehrDepartment of Radiation Oncology, University Medical Hospital, Hamburg-Eppendorf, Hamburg, Germany.
Annika HardtDepartment of Radiotherapy and Radiation Oncology, Outpatient Center of the University Medical Hospital Hamburg-Eppendorf, Hamburg,, Germany.
Raphael BodensohnDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Lukas KäsmannDepartment of Radiation Oncology, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Maria WaltenbergerDepartment of Radiation Oncology, Hospital of Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.
Eleni GkikaDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Bonn, Bonn, Germany.
Davide ScafaDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Bonn, Bonn, Germany.
Julian P LayerDepartment of Radiation Oncology, Faculty of Medicine and University Hospital Bonn, Bonn, Germany.
Esther G C TroostOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden- Rossendorf, Institute of Radiooncology - OncoRay Helmholtz- Zentrum Dresden-Rossendorf, Dresden, Germany.
Sally A ElkhamisyNational Center for Tumor Diseases (NCT/UCC), Dresden, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany, Medizinische Fakultät and University, Hospital Carl Gustav Carus Technische Universität Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Danny JazmatiUniversity Hospital Dusseldorf, Medical Faculty, Heinrich-Heine-University Dusseldorf, Department of Radiation Oncology, Dusseldorf, Germany.
Ilinca PoppDepartment of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany.
Sebastian NepplDepartment of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Anna HagemeierInstitute of Medical Statistics and Computational Biology, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany.
Angela Besserer *Department of Radiation Oncology, Ernst von Bergmann Hospital Potsdam, Potsdam, Germany.
Simone Ferdinandus *Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Abscopal effects (AbE) during combined radiotherapy (RT) and immune checkpoint inhibition (ICI) represent a potential mechanism for systemic tumor control, yet sex-specific differences in these responses remain largely unexplored. We investigated sex-associated signals in outcomes of combined RT-ICI in a multicenter cohort. We analyzed the incidence of AbE and survival outcomes with respect to clinical and biomedical markers. Methods: In this observational multicenter study, patients with metastatic solid tumors receiving RT-ICI and showing at least one non-irradiated lesion (NIL), assessed using iRECIST criteria, were analyzed. Abscopal response (AR) was defined as ≥30% reduction in NIL size, abscopal progression (AP) as ≥20% increase, and abscopal control (AC) as changes within this range. Results: Among 3,773 screened patients, 142 met the inclusion criteria (62% male, median age 62 years; 38% female, median age 58 years). AR and AC occurred more frequently in females (24% vs. 14%, 35% vs. 31%). While OS showed no significant difference (p=0.81), Cox regression analyses revealed significant associations of a longer ICI-to-RT-interval (males: HR = 0.903 [0.833-0.978], p=0.012; females: HR = 0.748 [0.621-0.900], p=0.002) and a BMI ≥25 kg/m² with survival in both sexes (males: HR = 4.282 [1.473-12.446], p=0.008; females: HR = 4.801 [1.182-19.502], p=0.028 with survival in both sexes). Elevated C-reactive protein (CRP) (≥5 mg/L) showed prognostic significance only in males (HR = 4.764 [1.184-19.170], p=0.028). Conclusion: Our findings suggest the possibility of sex-specific patterns in AbE occurrence. Additionally, our analyses identified sex-associated prognostic factors, including the importance of ICI-to-RT interval and BMI in both sexes and the male-specific prognostic value of CRP. These observations warrant further research and consideration in designing personalized RT-ICI combination strategies.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsAgedFemaleHumansMaleMiddle AgedSex FactorsTreatment Effect HeterogeneityTreatment OutcomeImmune Checkpoint Inhibitorsabscopal effectsimmune checkpoint inhibitionradioimmunotherapysex-specific immune effectssex-specific radiation oncology

Identifiers

PMID41704534
PMCPMC12907404

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.